Bioavailability Study of Candesartan Cilexetil 16mg Tablet Under Fasting Conditions
Status:
Completed
Trial end date:
2014-01-22
Target enrollment:
Participant gender:
Summary
This will be an open-label, randomized, single dose, two-way crossover study. Each subject
will participate in both treatment periods and will receive single oral doses of candesartan
cilexetil (GW615775) and reference candesartan cilexetil (ATACAND™); the treatment periods
will be separated by a washout period of at least 7 days and no greater than 14 days. This
study aims to determine the relative bioavailability of a 16mg test formulation tablet of
candesartan cilexetil (GW615775) compared to an 16mg reference tablet of candesartan
cilexetil in healthy adult subjects. ATACAND is a registered trademark of the Astra/Zeneca
group of companies.